Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : corgenix -- Ignore unavailable to you. Want to Upgrade?

To: RikRichter who wrote (175)	11/18/2009 11:22:39 PM
From: RikRichter	Respond to of 191

Corgenix Medical Corporation (CONX) Partners with Medison Pharma Ltd. to Bring Aspirinworks Urine Tests For Heart Disease Sufferers To Israel 11/17/2009 1:44:29 PM Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, has signed an exclusive agreement with the Medison Group to market its AspirinWorks test kits in Israel. This will allow individuals with risk of heart attack to rapidly determine if aspirin therapy is effective for them. The AspirinWorks® Test Kit is an enzyme-linked immunoassay (ELISA) to determine levels of 11-Dehydro Thromboxane B2 (11dhTxB2) in human urine, which aids in the qualitative detection of aspirin effect in apparently healthy individuals post ingestion. Its strong advantage is its ease of application. Unlike other platelet aggregation tests, which require freshly drawn blood that must be evaluated within 4 hours, AspirinWorks is non-invasive and requires only a urine sample that can easily be obtained in any doctor’s office. It is not time-sensitive. “Research has shown that up to 25 percent of individuals may be non-responsive to aspirin’s benefits, and are more than three times more likely to die from heart disease,” said Corgenix Clinical Affairs Director Gordon Ens. “This test can tell us if the aspirin fails to elicit an effect, thereby allowing physicians to individualize their patient’s therapy.” The AspirinWorks® diagnostic test kit targets a potential U.S. market of over 60 million individuals and a potential global market exceeding 200 million individuals. More than one million Americans experience new or recurrent heart attacks each year.